Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
159.50
Ask:
164.00
Spread: 4.50 (2.821%)
Market Cap: £1.38b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

22 May 2007 07:00

Hutchison China Meditech Limited22 May 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Director's Shareholding London: Tuesday, 22 May 2007: Chi-Med was informed on 18 May 2007 that Mr.Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med,purchased 70,000 ordinary shares of US$1 each in Chi-Med (the "Shares") at aprice of 153p each on 18 May 2007. Following this purchase, Mr. Hogg is beneficially interested in 170,000 Sharesand vested option to subscribe for up to 384,091 Shares, representingapproximately 1.1% of the current issued share capital of Chi-Med. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888 Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights
30th Apr 20187:00 amRNSTotal Voting Rights
27th Apr 20181:52 pmRNSResults of Annual General Meeting
23rd Apr 20181:10 pmRNSGrant of Share Options under Share Option Scheme
23rd Apr 20181:05 pmRNSBlock Admission
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20187:00 amRNSVesting of awards under Long Term Incentive Plan
26th Mar 20187:00 amRNSAnnual Report & Notice of Annual General Meeting
21st Mar 20189:25 amRNSDirector's Share Dealing
20th Mar 20189:15 amRNSGrant of Share Options under Share Option Scheme
19th Mar 20187:10 amRNSDirector's Share Dealing
12th Mar 201811:22 amRNSPublication of Form 20-F
12th Mar 20187:02 amRNSFinal Results and Key Clinical Programs Update
6th Mar 20187:00 amRNSPhase Ib/II Trial of Epitinib in Glioblastoma
13th Feb 20187:01 amRNSEnrolment completed Ph III FALUCA Fruquintinib
5th Feb 20187:00 amRNSChi-Med to Announce 2017 Final Results
29th Dec 20177:00 amRNSBlock listing Interim Review
29th Dec 20177:00 amRNSTotal Voting Rights
15th Dec 20177:00 amRNSChi-Med Initiates Fruquintinib US Clinical Trials
1st Nov 20179:45 amRNSNotification of Major Holdings
1st Nov 20179:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
31st Oct 20177:00 amRNSFRUTIGA, a Phase III trial of Fruquintinib
30th Oct 20173:30 pmRNSClosing of U.S. Public Offering of ADSs
27th Oct 201712:10 pmRNSChi-Med Announces Over-allotment Option
26th Oct 20177:00 amRNSChi-Med Announces Pricing Raising US$262 million
25th Oct 20177:00 amRNSChi-Med Announces Proposed Offering of ADSs
19th Oct 20179:20 amRNSNotification of Major Interest in Shares
17th Oct 20177:00 amRNSSavolitinib Shows Encouraging Clinical Activity
16th Oct 20177:00 amRNSChi-Med Reports Preliminary Phase II data
12th Oct 20177:30 amRNSAppointment of Director
29th Sep 20177:04 amRNSSavolitinib and Fruquintinib presentations at WCLC
29th Sep 20177:00 amRNSOral Presentations at CSCO Annual Meeting
29th Sep 20177:00 amRNSTotal Voting Rights
31st Aug 201710:15 amRNSDirector's Share Dealing
29th Aug 20177:00 amRNSStart of HMPL 689 Phase I Trial in China
22nd Aug 20179:00 amRNSDirector's Share Dealing
18th Aug 201710:50 amRNSDirectors' Share Dealing
15th Aug 201710:30 amRNSDirectors' Share Dealing
10th Aug 20179:35 amRNSDirector's Share Dealing
7th Aug 20179:45 amRNSDirectors' Share Dealing
31st Jul 20177:00 amRNSChi-Med Reports 2017 Interim Results
30th Jun 20177:00 amRNSTotal Voting Rights
29th Jun 20177:00 amRNSChi-Med to Announce 2017 HY Financial Results
29th Jun 20177:00 amRNSBlocklisting Six Monthly Return
29th Jun 20177:00 amRNSStart of Savolitinib Global PRCC Phase III Trial
22nd Jun 20177:00 amRNSChi-Med starts Ph I/II Trial of HMPL 453 in China
16th Jun 20179:57 amRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.